Abstract
It is well known that RA (Rheumatoid arthritis) is an autoimmune disease characterized by multiple and symmetric arthropathy. The main pathological features of RA are synovial hyperplasia, angiogenesis, pannus formation, inflammatory cell infiltration, articular cartilage, bone destruction, and ultimately joint dysfunction, even deformity. IL-35 (Interleukin-35) is a new member of the IL-12 (Interleukin-12) family, which is an immunosuppressive and anti-inflammatory cytokine secreted mainly by Treg (T regulatory cells). There is evidence suggested that IL-35 can attenuate the progression of RA through influencing the immune and pathological process. It suggests that IL-35 played an important role in the pathogenesis of RA, and can be used as a potential target for the future treatment of RA. This review summarizes the recent advances of IL-35 in the pathological roles and the therapeutic potential roles in RA.
Highlights
1. IL-35 is an inhibitory cytokine that closely related to the occurrence and development of RA.
2. IL-35 can induce the proliferation of Treg and inhibit the differentiation of Th17.
3. IL-35 can relieve the symptoms of RA greatly by inhibiting the proliferation of FLS, angiogenesis, and bone destruction.
Introduction
RA is an autoimmune disease characterized by multiple and symmetric arthropathy (El et al., 2007). It is associated with a significant morbidity and disability rate. Recent epidemiological investigations reveals that the total incidence of RA is 1–2% in the world. If untreated, the 2–3 years disability rate of RA can be as high as 70% (Jutley et al., 2015). It seriously affects the living quality. The main pathological features of RA are synovial hyperplasia, angiogenesis, pannus formation, inflammatory cell infiltration, articular cartilage, bone destruction, and ultimately joint dysfunction, even deformity (Turk et al., 2014; Elshabrawy et al., 2015). Although the specific pathogenesis of RA is very complicated, it is considered that the incidence of RA is related to the IL-12 family (Guan et al., 2017).
IL-12 family is composed of IL-12, IL-23, IL-27, IL-35. It helps to regulate the immune system against from infectious diseases, tumors, autoimmune disease (Gee et al., 2009). As a new member of the IL-12 family, IL-35 is first found in the supernatant of B lymphoblastoid cells infected by Epstein-Barr virus in 2007 (). IL-35 is an immunosuppressive and anti-inflammatory cytokine which mainly secrets by Tregs (). It can induce the proliferation of Tregs and inhibit the differentiation of Th17 (T Helper cell 17) cells (Wang et al., 2014; ). IL-35 is closely related to the occurrence of infections, inflammation, tumors, autoimmune diseases, such as primary biliary cirrhosis, Crohn’s disease, systemic sclerosis, and RA (Kong et al., 2016; Zou et al., 2017; Teymouri et al., 2018; Zhao et al., 2020; Zhu et al., 2020).
Collectively, these data suggests that exploring the biological functions and mechanisms of IL-35 may play a pivotal role in the pathogenesis of RA. The present review provides a brief overview of the IL-35, discusses the IL-35 involves in the pathogenesis of RA, and the therapeutic potential of IL-35 in RA.
Overview of IL-35
IL-35 is a new type of cytokine discovered simultaneously by Collison et al. and Niedbala et al., in 2007 (; Niedbala et al., 2007). It is combined with IL-12, IL-23, and IL-27 to form the IL-12 family (). IL-35 is constituted by A chain (p35/IL-12a) and B chain (EBI3/IL-27b) (Su et al., 2018). The glycoprotein encoded by the p35 gene is homologous with IL-6 and G-CSF (granulocyte colony-stimulating factor) and determined the specificity of cytokines. The EBI3 (Epstein-Barr virus-induced gene 3) gene encodes a glycoprotein with a relative molecular weight of 34,000, and 27% of the amino acid sequences are homologous to IL-12 and p40 subunits that belong to the hematopoietic cytokine receptor family (). The p35 and EBI3 gene are located on separated chromosomes 3p12-q13.2 and 19p13.3, respectively, in humans; chromosomes 6 and 17qD in the mouse (). (Figure 1) Moreover, subunits of the IL-35 receptor are shared among IL-12 family members. IL-35 receptors are consisted of IL12Rb2 (IL-12 receptor component) and gp130 (glycoprotein130) (IL-27 receptor component) ().
FIGURE 1
IL-35 is directly secreted by regulatory T cells, including thymic Tregs and peripheral Tregs (Pflanz et al., 2002). Evidence shows that CD4+CD25+Foxp3+Tregs can secrete IL-35 in both humans and mice (Kaser et al., 2012), and a class of iTreg (induced-Treg) called iTr35 (IL-35 induced Treg) can also secrete IL-35 (). Besides, a series of non-immune cells including tumor cells can also secrete IL-35 (Long et al., 2013; Wang et al., 2013). In general, IL-35 is inducible in Tregs, Bregs, immature dendritic cells, vascular endothelial cells, epithelial cells, and smooth muscle cells in the human body (Shen et al., 2014; ; Haller et al., 2017; Mohd Jaya et al., 2019). Two subunits of IL-35 have a high expression level in mice, and the p35 subunit is revelated in blood, liver, thymus, and bone marrow (Li et al., 2012). Besides, IL-35 is found in patient’s serum with RA (Li et al., 2019a), and IL-35 mRNA expression in RA patients is obviously lower (Zhang et al., 2018). It means that the secretion of IL-35 is difference in different tissue. The expression level change of IL-35 in RA patients suggests that it may participate in the pathogenesis of RA.
IL-35 Participates in the Pathogenesis of RA
IL-35 participates in various immune-related diseases, such as primary biliary cirrhosis, Crohn’s disease, and RA (Remmers et al., 2010; ; ; Zhao et al., 2020). The influence of IL-35 in the pathogenesis of RA is closely related to the immune dysfunction of these immune cells and pathological process (Figure 2). IL-35 promotes the proliferation of Tregs and inhibited the differentiation of Th17 cells (Liu S. et al., 2019). A variety of immune cells including Tregs and Th17 cells infiltrates into the joint and are crucial for synovial inflammation and joint destruction (Wang and Lei, 2021). Therefore, IL-35 playss an important role in the pathological process of RA by maintaining the balance of Tregs and Th17 cells.
FIGURE 2
IL-35 Influences the Balance of Immune Cells
IL-35 is directly secreted by Tregs. The variation of the number of Tregs was accompanied by a defect in its function (Lin et al., 2014; Li et al., 2019), and the number of Tregs was found decreased in peripheral blood with active RA patients (Wang et al., 2012). Coincidentally, two chains that constituted IL-35, mRNA of EBI3 and IL-12p35 were found continuously co-expressed at a high expression level in Tregs (). It meaned that the occurrence of RA was closely related to the number and function of Tregs, and IL-35 played an important role in exerting the maximal immunosuppressive function of Tregs. Tregs exerted immunostimulatory activity mainly by EBI3, which could induce macrophages to synthesize macrophage inflammatory protein-1 and further recruit B and T lymphocytes to inflammatory sites (Liu et al., 2012). Further research showed that IL-35 could promote the proliferation of Tregs (Wang and Lei, 2021). A class of Treg called iTR35 cells presented high reactivity and strong inhibition of inflammation by transforming initial T cells into a new type of Foxp3−Treg (Forkhead Box P3) (), but it was irrelevant to IL-10, TGF-β (transforming growth factor-β), and other Treg-related immune molecules (Hori et al., 2017). More importantly, iTR35 cells were more stable in vivo and had a more durable immune tolerance effect compared with Tregs (Song and Ma, 2016). In addition to the stimulation of recombinant IL-35, it was confirmed that human Tregs derived from umbilical cord blood or adult peripheral blood mononuclear cells could also induce initial T cells to transform into iTR35 cells by secreting IL-35 (). Taken together, IL-35 might have a significant impact on RA by promoting the differentiation of Tregs.
IL-35 also inhibited the differentiation of Th17 cells. There was a balance between Th17 cells and Tregs under different cell induction conditions, while high concentrations of TGF-β made the balance come to the Tregs (Williams et al., 2013). It was found that in vitro derived EBI3−/− Th17 cells could produce a significantly higher expression level of IL-17 and IL-22. Spleen cells from EBI3−/− mice immunized with monocytogenes could also produce elevated expression levels of IL-17 and IL-22 (Yang et al., 2008). A study suggested that IL-35 could directly suppress IL-17 expression and Th17 differentiation (Veldhoen et al., 2006). Furthermore, it was found that the differentiation of Th17 cells was accelerated by TGF-β, while IL-35 could significantly up-regulate the expression level of IFN-γ (Interferon-γ) to inhibit the phosphorylation of Smad-3, a downstream effector of TGF-β receptor, and IL-35 could prevent the binding of TGF-β and its receptor to block the differentiation of Th17 cells (Park et al., 2005). Moreover, there was research that found peripheral blood mononuclear cells which stimulated with IL-35, could inhibit the differentiation and the function of Th17 cells by reducing the relative expression of ROR γt (Nuclear receptor γt) (Xie et al., 2020). Taking all the studies into account, IL-35 could suppress the activity of Th17 cells and play a negative role in the pathogenesis of RA.
IL-35 Influenced the Pathological Features of RA
The main pathological features of RA are synovial hyperplasia, angiogenesis, pannus formation, inflammatory cell infiltration, articular cartilage, bone destruction, and ultimately joint dysfunction. IL-35 is indicated to participate in the pathological process of RA through several reports.
RA pathogenesis is highly correlated with FLS (Fibroblast-like synoviocytes) which release proteolytic enzymes produced by inflammatory cytokines, such as MMPs (matrix metalloproteinase) (). Pro-inflammatory cytokines such as IL-6, IL-8, TNF-α, IL-1β, which causing activation of FLS led to synovial inflammations. IL-35 can restrain the process (). In a previous experiment, IL-35 inhibits the proliferation and cell cycle progression in FLS which is harvested from CIA mice (Collagen-induced model of RA mice) in a dose-dependent manner. This consequence is accompanied by the downregulation of cyclin D1 (Li et al., 2016a). It indicates that IL-35 inhibits the proliferation of FLS and promoted the apoptosis of FLS directly.
Synovium hyperplasia in RA is accompanied by angiogenesis () and is a key process in the development of RA. It suggests that RA can be considered as a type of vascular disease, and foster pannus formation, persistent leukocyte infiltration, lining layer hyperplasia, which conclusively lead to cartilage and bone destruction (Szekanecz et al., 2010). Research shows angiogenesis is promoted by VEGF (vascular endothelial growth factor), which is critical in the pannus formation in synovial tissues and plays an important role in RA (Kim et al., 2015). IL-35 is found to downregulate the expression level of VEGF and its receptors in the CIA mice, which shows that IL-35 might influence the pathological procedure of RA (Wu et al., 2016a). The probable mechanisms relied on inhibiting VEGF and its receptors. Except for VEGF, IL-35 can also affect the EC specific factors Ang1, Ang2 (angiopoietin-1) in pathological vascular development. IL-35 is ECs (human umbilical endothelial cells) and RA synovial tissue explants (Jiang et al., 2016a). Thus, this evidence suggests that IL-35 may play a role in antagonizing angiogenesis in the pathological procedure of angiogenesis and pannus formation.
Bone destruction is also one of the most prominent features of RA pathogenesis. It is generally known that the formation and differentiation of osteoclasts rely on the activation of the RANKL receptor (nuclear factor κB ligand) (Tanaka et al., 2018). Previous research suggests that RANKL have a trend of up-regulation in the RA synovial tissues (Gravallese et al., 2000; Liu et al., 2018). Li Y et al. investigates that IL-35 can inhibit the development of RA in CIA mice by a decrease in the expression level of RANKL and an increase in the expression level of OPG (osteoclastogenesis inhibitory factor) (Li et al., 2016a). Additionally, IL-35 is found synergistically inducing osteoclast formation with RANKL (Kamiya et al., 2020). It means IL-35 may play both destructive and protective roles in the formation of osteoclasts. Besides, IL-35 can also inhibit the secretion of MMPs in chondrocytes and synovial fibroblasts and enhance the activities of aggrecanases and collagenase to promote the degradation of cartilage proteoglycan and collagen and heighten the destruction of osteoclasts (Shui et al., 2017; Liu X. et al., 2019; Sun et al., 2019). It means IL-35 do contribution to prevent cartilage matrix and bone destruction. To sum up, IL-35 participates in the pathogenesis of RA, and it has a benefit of teasing out the regulatory mechanism of IL-35 in RA.
The Regulatory Mechanism of IL- 35 in RA
IL-35 is acknowledged as involved in the pathogenesis of RA by regulating the expression level of pro-inflammatory cytokines (). Its specific regulatory mechanism in RA has been extensively studied in recent years. IL-35 is considered to activate several signal transduction pathways, including JAK-STAT (Janus Kinase-signal transducer and activator of transcription), Ang2-Tie2 (TEK Tyrosine kinase, Endothelial), and Wnt-β-catenin signaling pathways which regulated the procedure of RA.
Evidence points that the signaling pathway of RA may relate to the JAK-STAT family (Veale et al., 2017). The signaling molecules of the JAK-STAT signaling pathway includes the JAK2, Tyk2, and STAT family (Thierfelder et al., 1996). A study find IL-35 can activate the JAK1 signal transducer and activator of the STAT pathway in vitro (). Specifically, two receptors of IL-35, gp130, and IL-12Rβ2, respectively, activates JAK2 and Tyk2 through phosphorylation. The heterodimers or homologous dimers composed of gp130 and IL-12Rβ2 emits signals transferring into the nucleus with activation of the STAT family, then regulated cytokine-specific gene expression and exerting biological effects (Parham et al., 2002). Study find IL-35 increases the expression level of p-STAT1 in FLS, but do not affect the expression level of p-STAT3 and p-STAT5 (Wu et al., 2018). Additionally, JAK inhibitors Tofacitinib is used in RA patients and find that serum expression level of IL-35 is significantly increased (Li et al., 2019). The above results shows that IL-35 can act through the JAK-STAT signaling pathway. Moreover, emerging evidence shows that the phosphorylated (p)-STAT3 is downregulated, and p-STAT1/4 is upregulated in IL-35 overexpressed cells (). These results indicates that IL-35 may impact inflammation through STAT1/4. While the structures and signal transduction of the IL-35 are similar to the other member of IL-12 family, the biological activities are quite opposite (Tait et al., 2019). Therefore, IL-35 may have other unique receptors, and the detailed mechanism needs further study (Figure 3). Thus, it is considered that the signal transduction of IL-35 in the regulation mechanism of RA is closely related to the JAK2, Tyk2, and STAT family.
FIGURE 3
Evidence shows that the Ang-Tie2 signaling pathway mediates the pathological process of RA (Kayakabe et al., 2012). The role of the Ang-Tie2 signaling pathway is mainly angiogenesis (Vanderborght et al., 2020). In an earlier study, it is observed that constitutive expression of Ang-1 and Ang-2 in late-stage RA synovial fibroblasts (Scott et al., 2002). Recent study shows that Ang-1 and Ang-2 are found to enhance the expression level of pro-inflammatory cytokines in macrophages from donors with RA (Kabala et al., 2020), and evidence shows Tie2 significantly inhibit angiogenesis by neutralizing the Ang2 receptor (Saber et al., 2011). Meanwhile, IL-35 inhibits Ang2 secretion and antagonized the proangiogenic effects of exogenous Ang2 in HUVECs(Jiang et al., 2016b). These results suggests that IL-35 restrained RA angiogenesis and inflammation by disrupting the Ang2-Tie2 signaling pathway.
In addition, studies have shown that the Wnt-β-catenin signaling pathway is also involved in the pathogenesis of RA. The Wnt proteins are glycoproteins which lead to joint formation (Miao et al., 2013), and the Wnt-β-catenin signaling pathway influences the subchondral bone remodeling (Kovacs et al., 2019). Evidence shows Wnt signaling is up-regulated in RA FLS (Sen et al., 2002). The Wnt genes are revealed significant up-regulation in RA patients synovium, and are present in articular cartilage, bone, and synovium of RA patients (Nakamura et al., 2005). Besides, the expression level of Wnt inducible signaling pathway proteins is also found significantly elevated in RA FLS (). A study shows that the serum expression level of Dkk-1 (Dickkopf-1), an inhibitor of the Wnt-β-catenin signaling pathway, is significantly higher in patients with RA (Wang et al., 2011). It suggests that the Wnt-β-catenin signaling pathway plays a key role in bone resorption and joint destruction during RA development. Meanwhile, it shows that IL-35 activates osteoblastic differentiation via the Wnt-β-catenin signaling pathway in RA, and this result can be resulted by pairing of IL-35 and Dkk-1 (Li et al., 2019). As support, IL-35 is found dose-dependently inhibited the expression level of RANKL and increased the expression level of OPG in cultured FLS, which mainly plays a part through the Wnt-β-catenin signaling pathway (Li et al., 2016b). Therefore, IL-35 may influence the bone resorption and joint destruction in RA by the Wnt-β-catenin signaling pathway.
The Therapeutic Potential Role of IL-35 in RA
As a potential target, IL-35 is more considered as a monitoring indicator when exploring the pathogenesis of RA (Li et al., 2019; Wojdasiewicz et al., 2019)or predicting the efficacy of certain drugs (Li et al., 2019). Several reports shows the potential of IL-35 in the therapy of RA.
Study shows that IL-35 is secreted in the joint tissue homogenate of CIA mice, and inhibits the inflammatory response of macrophages (Wang and Zhong, 2015). Evidence shows a decreasing arthritis index, and promoting apoptosis in CIA mice, which is injected with IL-35 intraperitoneally (Li et al., 2016b). Moreover, by upregulating the secretion of IL-35, it is found that IL-35 reduces antigen-specific local inflammation and impaired disease development of RA in CIA mice (Yin et al., 2016; Koga et al., 2021). Besides, the antagonist of IL-35 is injected into the joint space and exerted the highest anti-inflammatory effects (). IL-35 is also found dose-dependently inhibiting the expression level of RANKL and increasing the expression of OPG (Li et al., 2016c). Moreover, it downregulates the expression level of VEGF and its receptors in CIA mice, which is important for angiogenesis (Wu et al., 2016b). While another study shows similar consequences by using a murine Matrigel plugs model (Jiang et al., 2016c). Taking all these studies into account, IL-35 can inhibit the development of RA effectively in mice. But, It also shows a statistically significant increase in clinical scores of CIA after receiving an injection of two distinct plasmids encoding IL-35 gene 3 and 18 days in CIA mice (Thiolat et al., 2014). It means that IL-35 may be elevated in early RA and play a negative role.
Notably, secretion of IL-35 is investigated in synvium from RA patients, and EBI-3/p35 transcripts are expressed (Kam et al., 2018a). A study shows that IL-35 suppressed T cell activation during the peripheral immune responses of RA patients (Li et al., 2019b), and evidence shows IL-35 has a lower expression level in peripheral blood of RA patients than controls (Sun et al., 2015). Several studies have confirmed this result (Ning et al., 2015; Xie et al., 2021). It suggests that IL-35 correlates with the pathogenesis of RA in vivo. The serum expression level of IL-35 and the number of Tregs are found to decrease significantly in peripheral blood harvested from patients with RA (Nakano et al., 2015a). Further studies show that low expression level of serum IL-35 correlates with high ESR and DAS28-ESR (DAS28 erythrocyte sedimentation rate) in RA patients (Li et al., 2019c). Thus, the expression level of IL-35 is correlated with the severity of RA. The study evaluates the effect of IL-35 on human osteoclastogenesis, and find it significantly decreased the expression level of RANK mRNA in monocytes in a dose-dependent manner (Yago et al., 2018). Besides, IL-35 shows an inhibiting effect on endothelial cell migration, adhesion, and tube formation in HUVEC (Jiang et al., 2016d). It indicates that IL-35 may have therapeutic potential for RA by inhibiting osteoclastogenesis and angiogenesis. Interestingly, a study shows the expression level of serum IL-35 is significantly higher in patients with treatment naïve early RA compared to controls, and significantly decreased after treatment (Jiang et al., 2016d). It may provide us an opportunity to control early RA by regulating the expression level of IL-35 in the human body. Thus, it is imperative to find a way for IL-35 to play a greater role in RA treatment.
TABLE 1
| Cytokines | Producing cells | Function | References |
|---|---|---|---|
| IL-12 | monocytes, macrophages,DCs,B cells | Th1 differentiation; Th2 inhibition; IFN-γ↑ | Wu et al. 2016 |
| IL-23 | monocytes, macrophages,DCs,B cells, endothelial cells | Th17 differentiationIL-17↑ ; Proliferation of CD4+ memory T cells | Nakano et al. 2015b |
| IL-27 | macrophages,DCs,B cells | Inhibition of immune system responses; limit the inflammatory | |
| IL-35 | Tregs, breg, endothelial cells; monocytes | Treg and breg differentiation; iTR35 differentiation; Th17 inhibition; teff inhibition; IL-35 and IL-10 ↑; M1macrophages↓; M2macrophages↑ |
IL-12 family in RA.
TABLE 2
| Modulators | IL-35 | Target | Model | References |
|---|---|---|---|---|
| IL-35 | IFN-γ | RA serum | Niedbala et al. 2007 | |
| Breg | IL-35 | IL-10 | PBMCs | Wang et al. 2014 |
| iTR35 | IL-35 | IL-35 | Mice | |
| IL-35 | TNF-α | FLS | Wu et al. 2016c | |
| Endothelial cells | IL-35 | Ang2 | Huvec | Jiang et al. 2016a |
| IL-35 | RANKL | FLS | Li et al. 2016a | |
| IL-35 | OPG | CIA mice | Li et al. 2016d | |
| IL-35 | P-STAT1 | FLS | Wu et al. 2018 | |
| IL-35 | VEGF | FLS | Wu et al. 2018 | |
| Macrophages | IL-35 | CCR-7 | PBMCs | Peng et al. 2019 |
| CD39+CD4+T cells | IL-35 | Foxp3 | Arthritis mice | Filkova et al. 2015 |
| Th-17 | IL-35 | IL-17 | Mice spleen cells | Kam et al. 2018b |
The targets of IL-35 in RA.
TABLE 3
| IL-35 | Sample | Expression change | References |
|---|---|---|---|
| IL-35 | RA synovium | Kam et al. 2018b | |
| IL-35 | Lyme arthritis/CIA mice tissue | + | Kuo et al. 2011 |
| IL-35 | Active RA serum | Kam et al. 2018b | |
| IL-35 | RA SF | + | Filkova et al. 2015 |
| IL-35 | Cultured FLS | + | Wu et al. 2018 |
| IL-35 | Normal human serum | Kam et al. 2018b |
Expression of IL-35 in RA.
+:up-regulation, —:down-regulation.
Future Perspectives
Since the discovery of IL-35, great progress has been made in exploring the expression, regulation, and function of IL-35 in autoimmune diseases. With the deepening research, the relationship between immune-related diseases such as RA and gut microbiota has been gradually discovered (Wu et al., 2016). Studies have shown that gut microbiota protected humans and mice away from RA by regulating intestinal and parenteral regulation. The intestinal immune response depends on the composition of microorganisms, which produces a series of enzymes, chemicals, hormones, vitamins, etc., that could interact with the metabolism of the host. When RA-related bacteria appeares in large quantities, the imbalance of gut microbiota reduces the growth of probiotics, thus inducing the incidence of RA (Maeda and Takeda, 2017; ), and the change of gut microbiota may occur before the onset of RA (Jeong et al., 2019). Evidence reveales that IL-12 can induce microbiota-driven chronic intestinal inflammation in inflammatory bowel disease (). Study shows the potential therapeutic utility of IL-12 about the gut microbiota, which in a murine model of chronic intestinal inflammation systemically treated with antibodies to IL-12 (), and IL-23 is found to regulated gut microbiota to trigger severe intestinal inflammation in animal models (Kullberg et al., 2006). Faecal samples are collected to analyze the microbiota community profiles using next-generation sequencing (Rehaume et al., 2019) and find an abundance of specific strains changed with disease severity in mice treated with anti-IL-23 (Manasson et al., 2020). Furthermore, evidence shows it can affect the composition of the gut microbiota by using IL-27 and antibody against IL-27 in mice (Lavoie et al., 2020). (Figure 4) To sum up, the research progress on gut microbiota could provides a choice for us to regulate intestinal and extraintestinal immune responses, and the IL-12 family including IL-12, IL-23, IL-27 could influence the progression of autoimmune diseases. Therefore, as a member of the IL-12 family, it is worth exploring whether IL-35 could also influence autoimmune diseases such as RA by affecting gut microbiota balance.
FIGURE 4
Meanwhile, growing gene-editing technology is offering help to treat various diseases through gene knockout or gene loss. For example, with CRISPR-Cas9 targeting the BCL11A erythroid-specific enhancer, γ-globin expression and fetal hemoglobin in erythroid cells is promoted in Transfusion-dependent β-thalassemia and sickle cell disease (Frangoul et al., 2021), and it is reported that CRISPR gene editing is used for cancer immunotherapy by CRISPR-Cas9 editing to engineer T cells in the treatment of refractory cancer (Stadtmauer et al., 2020). Generally, for precisely manipulating cellular DNA sequences and altering cell fates and organism traits, the technique of using CRISPR will soon be in the clinic for several diseases (). Moreover, CRISPR is already participated in the clinical application of autoimmune diseases (Safari et al., 2018). Study shows that M1/M2 monocytes imbalance strongly contributes to pathogenesis of RA (Fukui et al., 2017). CRISPR/Cas9 is used to knock out GRK2 gene, which has a capacity in regulating M1/M2 monocytes imbalance, and shows a potential for treating patients with RA by downregulating M1/M2 ratio (Tardito et al., 2019). Another study shows that miR-155 gene-knockdown macrophage cells are impaired in producing proinflammatory cytokines, but increased in osteoclastogenesis (Jing et al., 2015). A CRISPR/Cas9 system which target on IFN-γ gene is designed in inflammatory bowel disease mice models. It is observed that the IFN-γ is deficient, and the damage to the intestinal epithelial cells are prevented (Eftychi et al., 2019b). Taken together, CRISPR/Cas9 shows a potiential in changing the balance of immune cells or the secretion of inflammatory cytokines. Therefore, modulating the expression level of IL-35 through gene-editing technology may become a new therapy for RA.
Conclusion
In conclusion, as a new member of the IL-12 family, IL-35 is a heterodimeric protein composed of two subunits, EBI3, and IL-12p35. IL-35 is an inhibitory cytokine secreted mainly by Tregs and has a significant anti-inflammatory effect. It is widely involved in the immune response process in vivo and is closely related to the occurrence and development of inflammatory diseases such as RA. Furthermore, it can induce Tregs to produce iTR35 cells with stronger anti-inflammatory function and a more stable effect. At the same time, IL-35 can significantly inhibit the abnormal differentiation of Th17 cells to reduce the secretion of IL-17, and then effectively inhibits the development of inflammation. IL-35 can inhibit the proliferation of FLS, angiogenesis, and bone destruction caused by inflammation through JAK-STAT, Ang2-Tie2, and Wnt-β-catenin signaling pathways to relieve the symptoms of RA greatly. In clinical research, IL-35 shows that it plays an important role in the pathogenesis of RA, and it may be used as a potential target for the future treatment of RA with the further exploration of IL-35 function.
Statements
Author’s note
All authors made substantial contributions to all of the following: 1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content, 3) final approval of the version to be submitted.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Author contributions
LJ: first author, Design of the work, drafting the manuscript; PX: first author, Analysis and critical revision of the article, design of figures and tables; QC: Reviewing the pathological mechanism of RA; CD: corresponding author, Reviewing the regulation mechanism of IL-35 in RA and the potential of IL-35 in therapeutic of RA; DB: corresponding author, Analysis of pharmacological relevance, and final approval.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviation
RA, Rheumatoid arthritis; IL-35, Interleukin-35; IL-12, Interleukin-12; Treg, T regulatory cells; G-CSF, Granulocyte colony-stimulating factor; EBI3, Epstein-Barr virus-induced gene three; gp130, glycoprotein130; iTr35, IL-35 induced Treg; Foxp3, Forkhead Box p3; TGF-β, Transforming growth factor-β; FLS, Fibroblast-like synoviocytes; MMP, Matrix metalloproteinase; CIA mouse, Collagen-induced model of rheumatoid arthritis mouse; VEGF, Vascular endothelial growth factor; Ang, Angiopoietin; HUVECs, Human umbilical endothelial cells; RANKL-RANK, Receptor activator of NF-κB ligand/receptor activator of NF-ΚB; JAK-STAT, Janus Kinase-signal transducer and activator of transcription; Tie2, TEK Tyrosine kinase, Endothelial; Dkk-1, Dickkopf-1; DAS28-ESR, DAS28 erythrocyte sedimentation rate; Th17, T Helper cell; NF-κB, Nuclear factor kappa-B; OPG, Osteoclastogenesis inhibitory factor; IFN-γ, Interferon-γ.
References
1
AbdiE.NajafipourH.JoukarS.DabiriS.Esmaeli-MahaniS.AbbaslooE.et al (2018). Expression of IGF-1, IL-27 and IL-35 Receptors in Adjuvant Induced Rheumatoid Arthritis Model, Iran. J. Immunol., 15, 14–27. IJIv15i1A2
2
AfzaliB.LombardiG.LechlerR. I.LordG. M. (2007). The Role of T Helper 17 (Th17) and Regulatory T Cells (Treg) in Human Organ Transplantation and Autoimmune Disease. Clin. Exp. Immunol.148 (1), 32–46. 10.1111/j.1365-2249.2007.03356.x
3
AllyM. M. T. M.HodkinsonB.MeyerP. W. A.MusengeE.TintingerG. R.TiklyM.et al (2015). Circulating Anti-citrullinated Peptide Antibodies, Cytokines and Genotype as Biomarkers of Response to Disease-Modifying Antirheumatic Drug Therapy in Early Rheumatoid Arthritis. BMC Musculoskelet. Disord.16 (1), 130. 10.1186/s12891-015-0587-1
4
BalakrishnanB.LuckeyD.TanejaV. (2019). Autoimmunity-Associated Gut Commensals Modulate Gut Permeability and Immunity in Humanized Mice. Mil. Med.184 (Suppl. 1), 529–536. 10.1093/milmed/usy309
5
BehzadiP.BehzadiE.RanjbarR. (2016). IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways. Acta Microbiologica et Immunologica Hungarica63 (1), 1–25. 10.1556/030.63.2016.1.1
6
BettiniM.CastellawA. H.LennonG. P.BurtonA. R.VignaliD. A. A. (2012). Prevention of Autoimmune Diabetes by Ectopic Pancreatic -Cell Expression of Interleukin-35. Diabetes61 (6), 1519–1526. 10.2337/db11-0784
7
BobryshevY.SobeninI.OrekhovA.ChistiakovD. (2015). Novel Anti-inflammatory Interleukin-35 as an Emerging Target for Antiatherosclerotic Therapy. Cpd.21 (9), 1147–1151. 10.2174/1381612820666141014123810
8
Bossini-CastilloL.MartinJ.-E.BroenJ.GorlovaO.SimeonC. P.BerettaL.et al (2012). A GWAS Follow-Up Study Reveals the Association of the IL12RB2 Gene with Systemic Sclerosis in Caucasian Populations. Hum. Mol. Genet.21 (4), 926–933. 10.1093/hmg/ddr522
9
CaiZ.ZhangS.WuP.RenQ.WeiP.HongM.et al (2021). A Novel Potential Target of IL‐35‐regulated JAK/STAT Signaling Pathway in Lupus Nephritis. Clin. Translational Med.11 (2), e309. 10.1002/ctm2.309
10
ChaturvediV.CollisonL. W.GuyC. S.WorkmanC. J.VignaliD. A. A. (2011). Cutting Edge: Human Regulatory T Cells Require IL-35 to Mediate Suppression and Infectious Tolerance. J.I.186 (12), 6661–6666. 10.4049/jimmunol.1100315
11
ChehbounS.Labrecque-CarbonneauJ.PasquinS.MelianiY.MeddahB.FerlinW.et al (2017). Epstein-Barr Virus-Induced Gene 3 (EBI3) Can Mediate IL-6 Trans-signaling. J. Biol. Chem.292 (16), 6644–6656. 10.1074/jbc.M116.762021
12
ChenZ.BozecA.RammingA.SchettG. (2019). Anti-inflammatory and Immune-Regulatory Cytokines in Rheumatoid Arthritis. Nat. Rev. Rheumatol.15 (1), 9–17. 10.1038/s41584-018-0109-2
13
CheonH.BoyleD. L.FiresteinG. S. (2004). Wnt1 Inducible Signaling Pathway Protein-3 Regulation and Microsatellite Structure in Arthritis. J. Rheumatol.31 (11), 2106–2114.
14
ChoiJ.LeungP. S. C.BowlusC.GershwinM. E. (2015). IL-35 and Autoimmunity: a Comprehensive Perspective. Clinic Rev. Allerg Immunol.49 (3), 327–332. 10.1007/s12016-015-8468-9
15
CollisonL. W.ChaturvediV.HendersonA. L.GiacominP. R.GuyC.BankotiJ.et al (2010). IL-35-mediated Induction of a Potent Regulatory T Cell Population. Nat. Immunol.11 (12), 1093–1101. 10.1038/ni.1952
16
CollisonL. W.DelgoffeG. M.GuyC. S.VignaliK. M.ChaturvediV.FairweatherD.et al (2012). The Composition and Signaling of the IL-35 Receptor Are Unconventional. Nat. Immunol.13 (3), 290–299. 10.1038/ni.2227
17
CollisonL. W.VignaliD. A. A. (2008). Interleukin-35: Odd One Out or Part of the Family?Immunol. Rev.226 (1), 248–262. 10.1111/j.1600-065X.2008.00704.x
18
CollisonL. W.WorkmanC. J.KuoT. T.BoydK.WangY.VignaliK. M.et al (2007). The Inhibitory Cytokine IL-35 Contributes to Regulatory T-Cell Function. Nature450 (7169), 566–569. 10.1038/nature06306
19
DambuzaI. M.HeC.ChoiJ. K.YuC.-R.WangR.MattapallilM. J.et al (2017). IL-12p35 Induces Expansion of IL-10 and IL-35-expressing Regulatory B Cells and Ameliorates Autoimmune Disease. Nat. Commun.8 (1), 719. 10.1038/s41467-017-00838-4
20
DevergneO.HummelM.KoeppenH.Le BeauM. M.NathansonE. C.KieffE.et al (1996). A Novel Interleukin-12 P40-Related Protein Induced by Latent Epstein-Barr Virus Infection in B Lymphocytes. J. Virol.70 (2), 1143–1153. 10.1128/jvi.70.2.1143-1153.1996
21
DhimoleaE. (2010). Canakinumab. mAbs2 (1), 3–13. 10.4161/mabs.2.1.10328
22
DineshP.RasoolM. (2018). uPA/uPAR Signaling in Rheumatoid Arthritis: Shedding Light on its Mechanism of Action. Pharmacol. Res.134, 31–39. 10.1016/j.phrs.2018.05.016
23
DongY.LiX.YuY.LvF.ChenY. (2020). JAK/STAT Signaling Is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B. Life Sci.252, 117663. 10.1016/j.lfs.2020.117663
24
DoudnaJ. A. (2020). The Promise and Challenge of Therapeutic Genome Editing. Nature578 (7794), 229–236. 10.1038/s41586-020-1978-5
25
DuchmannR.SchmittE.KnolleP.Zum BüschenfeldeK.-H. M.NeurathM. (1996). Tolerance towards Resident Intestinal Flora in Mice Is Abrogated in Experimental Colitis and Restored by Treatment with Interleukin-10 or Antibodies to Interleukin-12. Eur. J. Immunol.26 (4), 934–938. 10.1002/eji.1830260432
26
EftychiC.SchwarzerR.VlantisK.WachsmuthL.BasicM.WagleP.et al (2019a). Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity51 (2), 367–380. 10.1016/j.immuni.2019.06.008
27
EftychiC.SchwarzerR.VlantisK.WachsmuthL.BasicM.WagleP.et al (2019b). Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity51 (2), 367–380. 10.1016/j.immuni.2019.06.008
28
ElB. D.MeddebN.SellamiS. (2007). [Rheumatoid Arthritis: Current Status of Therapy]. Tunis Med.85 (1), 1–8.
29
ElshabrawyH. A.ChenZ.VolinM. V.RavellaS.VirupannavarS.ShahraraS. (2015). The Pathogenic Role of Angiogenesis in Rheumatoid Arthritis. Angiogenesis18 (4), 433–448. 10.1007/s10456-015-9477-2
30
FilkováM.VernerováZ.HulejováH.PrajzlerováK.VeiglD.PavelkaK.et al (2015). Pro-inflammatory Effects of Interleukin-35 in Rheumatoid Arthritis. Cytokine73 (1), 36–43. 10.1016/j.cyto.2015.01.019
31
FrangoulH.AltshulerD.CappelliniM. D.ChenY.-S.DommJ.EustaceB. K.et al (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N. Engl. J. Med.384 (3), 252–260. 10.1056/NEJMoa2031054
32
FukuiS.IwamotoN.TakataniA.IgawaT.ShimizuT.UmedaM.et al (2017). M1 and M2 Monocytes in Rheumatoid Arthritis: A Contribution of Imbalance of M1/M2 Monocytes to Osteoclastogenesis. Front. Immunol.8, 1958. 10.3389/fimmu.2017.01958
33
GeeK.GuzzoC.Che MatN.MaW.KumarA. (2009). The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders. Iadt8 (1), 40–52. 10.2174/187152809787582507
34
GravalleseE. M.ManningC.TsayA.NaitoA.PanC.AmentoE.et al (2000). Synovial Tissue in Rheumatoid Arthritis Is a Source of Osteoclast Differentiation Factor. Arthritis Rheum.43 (2), 250–258. 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P
35
GuanS.-Y.LengR.-X.KhanM. I.QureshiH.LiX.-P.YeD.-Q.et al (2017). Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases. Inflammation40 (1), 303–310. 10.1007/s10753-016-0453-9
36
HallerS.DuvalA.MiglioriniR.StevaninM.MackV.Acha-OrbeaH. (2017). Interleukin-35-Producing CD8α+ Dendritic Cells Acquire a Tolerogenic State and Regulate T Cell Function. Front. Immunol.8 (8), 98. 10.3389/fimmu.2017.00098
37
HoriS.NomuraT.SakaguchiS. (2017). Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061. J. Immunol.198 (3), 981–985.
38
JeongY.KimJ.-W.YouH. J.ParkS.-J.LeeJ.JuJ. H.et al (2019). Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis. Jcm8 (5), 693. 10.3390/jcm8050693
39
JiangS.LiY.LinT.YuanL.LiY.WuS.et al (2016a). IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cell. Physiol. Biochem.40 (5), 1105–1116. 10.1159/000453165
40
JiangS.LiY.LinT.YuanL.LiY.WuS.et al (2016b). IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cel. Physiol. Biochem.40 (5), 1105–1116. 10.1159/000453165
41
JiangS.LiY.LinT.YuanL.LiY.WuS.et al (2016c). IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cel. Physiol. Biochem.40 (5), 1105–1116. 10.1159/000453165
42
JiangS.LiY.LinT.YuanL.LiY.WuS.et al (2016d). IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cel. Physiol. Biochem.40 (5), 1105–1116. 10.1159/000453165
43
JingW.ZhangX.SunW.HouX.YaoZ.ZhuY. (2015). CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits Proinflammatory Cytokine Production by RAW264.7 Cells. Biomed. Res. Int.2015, 1–7. 10.1155/2015/326042
44
JutleyG.RazaK.BuckleyC. D. (2015). New Pathogenic Insights into Rheumatoid Arthritis. Curr. Opin. Rheumatol.27 (3), 249–255. 10.1097/BOR.0000000000000174
45
KabalaP. A.Malvar-FernándezB.LopesA. P.CarvalheiroT.HartgringS. A. Y.TangM. W.et al (2020). Promotion of Macrophage Activation by Tie2 in the Context of the Inflamed Synovia of Rheumatoid Arthritis and Psoriatic Arthritis Patients. Rheumatology (Oxford)59 (2), 426–438. 10.1093/rheumatology/kez315
46
KamN.-W.LiuD.CaiZ.MakW.-Y.WongC.-K.ChiuK.-H.et al (2018a). Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with Osteoarthritis and Rheumatoid Arthritis. J. Rheumatol.45 (4), 563–573. 10.3899/jrheum.161363
47
KamN.-W.LiuD.CaiZ.MakW.-Y.WongC.-K.ChiuK.-H.et al (2018b). Synoviocytes-derived Interleukin 35 Potentiates B Cell Response in Patients with Osteoarthritis and Rheumatoid Arthritis. J. Rheumatol.45 (4), 563–573. 10.3899/jrheum.161363
48
KamiyaY.KikuchiT.GotoH.OkabeI.TakayanagiY.SuzukiY.et al (2020). IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells. Ijms21 (6), 2069. 10.3390/ijms21062069
49
KäserT.MüllebnerA.HartlR. T.EsslerS. E.SaalmüllerA.Catharina DuvigneauJ. (2012). Porcine T-Helper and Regulatory T Cells Exhibit Versatile mRNA Expression Capabilities for Cytokines and Co-stimulatory Molecules. Cytokine60 (2), 400–409. 10.1016/j.cyto.2012.07.007
50
KayakabeK.KuroiwaT.SakuraiN.IkeuchiH.KadiomboA. T.SakairiT.et al (2012). Interleukin-6 Promotes Destabilized Angiogenesis by Modulating Angiopoietin Expression in Rheumatoid Arthritis. Rheumatology51 (9), 1571–1579. 10.1093/rheumatology/kes093
51
KimH.-R.KimK.-W.KimB.-M.ChoM.-L.LeeS.-H. (2015). The Effect of Vascular Endothelial Growth Factor on Osteoclastogenesis in Rheumatoid Arthritis. PLoS One10 (4), e0124909, 10.1371/journal.pone.0124909
52
KogaM. M.EngelA.PigniM.LavanchyC.StevaninM.LaversenneV.et al (2021). IL10- and IL35-Secreting MutuDC Lines Act in Cooperation to Inhibit Memory T Cell Activation through LAG-3 Expression. Front. Immunol.12, 607315. 10.3389/fimmu.2021.607315
53
KongB.LiuG. B.ZhangJ. A.FuX. X.XiangW. Y.GaoY. C.et al (2016). Elevated Serum IL-35 and Increased Expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T Cells in Patients with Active Tuberculosis. Am. J. Transl. Res.8 (2), 623–633.
54
KovácsB.VajdaE.NagyE. E. (2019). Regulatory Effects and Interactions of the Wnt and OPG-RANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis. Ijms20 (18), 4653. 10.3390/ijms20184653
55
KullbergM. C.JankovicD.FengC. G.HueS.GorelickP. L.MckenzieB. S.et al (2006). IL-23 Plays a Key Role in Helicobacter Hepaticus-Induced T Cell-dependent Colitis. J. Exp. Med.203 (11), 2485–2494. 10.1084/jem.20061082
56
KuoJ.NardelliD. T.WarnerT. F.CallisterS. M.SchellR. F. (2011). Interleukin-35 Enhances Lyme Arthritis inBorrelia-Vaccinated and -Infected Mice. Clin. Vaccin. Immunol.18 (7), 1125–1132. 10.1128/CVI.00052-11
57
LavoieS.ChunE.BaeS.BrennanC. A.Gallini ComeauC. A.LangJ. K.et al (2020). Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response against Colorectal Tumors in Mice. Gastroenterology158 (5), 1359–1372. 10.1053/j.gastro.2019.12.027
58
LiH.YangD.TangZ. (2019). Bcl2 like Protein-12 Suppresses Foxp3+ Regulatory T Cells in Patients with Rheumatoid Arthritis. Am. J. Transl. Res.11 (5), 3048–3055. 10.1186/ar1718
59
LiX.MaiJ.VirtueA.YinY.GongR.ShaX.et al (2012). IL-35 Is a Novel Responsive Anti-inflammatory Cytokine - A New System of Categorizing Anti-inflammatory Cytokines. PLoS One7 (3), e33628. 10.1371/journal.pone.0033628
60
LiY.LiD.LiY.WuS.JiangS.LinT.et al (2016a). Interleukin-35 Upregulates OPG and Inhibits RANKL in Mice with Collagen-Induced Arthritis and Fibroblast-like Synoviocytes. Osteoporos. Int.27 (4), 1537–1546. 10.1007/s00198-015-3410-9
61
LiY.LiD.LiY.WuS.JiangS.LinT.et al (2016b). Interleukin-35 Upregulates OPG and Inhibits RANKL in Mice with Collagen-Induced Arthritis and Fibroblast-like Synoviocytes. Osteoporos. Int.27 (4), 1537–1546. 10.1007/s00198-015-3410-9
62
LiY.LiD.LiY.WuS.JiangS.LinT.et al (2016c). Interleukin-35 Upregulates OPG and Inhibits RANKL in Mice with Collagen-Induced Arthritis and Fibroblast-like Synoviocytes. Osteoporos. Int.27 (4), 1537–1546. 10.1007/s00198-015-3410-9
63
LiY.WuS.LiY.JiangS.LinT.XiaL.et al (2016d). Interleukin-35 (IL-35) Inhibits Proliferation and Promotes Apoptosis of Fibroblast-like Synoviocytes Isolated from Mice with Collagen-Induced Arthritis. Mol. Biol. Rep.43 (9), 947–956. 10.1007/s11033-016-4034-7
64
LiY.YaoL.LiuS.WuJ.XiaL.ShenH.et al (2019a). Elevated Serum IL-35 Levels in Rheumatoid Arthritis Are Associated with Disease Activity. J. Investig. Med.67 (3), 707–710. 10.1136/jim-2018-000814
65
LiY.YuanL.JiangS.LiuS.XiaL.ShenH.et al (2019b). Interleukin-35 Stimulates Tumor Necrosis Factor-α Activated Osteoblasts Differentiation through Wnt/β-Catenin Signaling Pathway in Rheumatoid Arthritis. Int. Immunopharmacology75, 105810. 10.1016/j.intimp.2019.105810
66
LiY.YuanL.YangJ.LeiY.ZhangH.XiaL.et al (2019c). Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis. Mediators Inflamm.2019, 1–8. 10.1155/2019/5617431
67
LinH.ZhangG. D.TangH. H.WangY.LiuY.ZhaoY. (2014). [The Change of CD4+ CD25+ Regulatory T Cells in Patients with Rheumatoid Arthritis]. Sichuan Da Xue Xue Bao Yi Xue Ban45 (4), 618–622.
68
LiuH. J.GuoX. F.HuF. L.YanC. P.CuiX. J.YanX. L.et al (2018). [Increased Receptor Activator of Nuclear Factor Kappa B Ligand Expressed on B10 Cells in Rheumatoid Arthritis]. Beijing Da Xue Xue Bao Yi Xue Ban50 (6), 968–974. 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z
69
LiuJ.-Q.LiuZ.ZhangX.ShiY.TalebianF.CarlJ. W.et al (2012). Increased Th17 and Regulatory T Cell Responses in EBV-Induced Gene 3-deficient Mice Lead to Marginally Enhanced Development of Autoimmune Encephalomyelitis. J.I.188 (7), 3099–3106. 10.4049/jimmunol.1100106
70
LiuX.ZhuY.ZhengW.QianT.WangH.HouX. (2019). Antagonism of NK-1R Using Aprepitant Suppresses Inflammatory Response in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Artif. Cell Nanomedicine, Biotechnol.47 (1), 1628–1634. 10.1080/21691401.2019.1573177
71
Liu, S.LiY.XiaL.ShenH.LuJ. (2019). IL-35 Prevent Bone Loss through Promotion of Bone Formation and Angiogenesis in Rheumatoid Arthritis. Clin. Exp. Rheumatol.37 (5), 820–825.
72
LongJ.ZhangX.WenM.KongQ.LvZ.AnY.et al (2013). IL-35 Over-expression Increases Apoptosis Sensitivity and Suppresses Cell Growth in Human Cancer Cells. Biochem. Biophysical Res. Commun.430 (1), 364–369. 10.1016/j.bbrc.2012.11.004
73
MaedaY.TakedaK. (2017). Role of Gut Microbiota in Rheumatoid Arthritis. Jcm6 (6), 60. 10.3390/jcm6060060
74
ManassonJ.WallachD. S.GugginoG.StapyltonM.BadriM. H.SolomonG.et al (2020). Interleukin‐17 Inhibition in Spondyloarthritis Is Associated with Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin‐25-Driven Intestinal Inflammation. Arthritis Rheumatol.72 (4), 645–657. 10.1002/art.41169
75
MiaoC.-g.YangY.-y.HeX.LiX.-f.HuangC.HuangY.et al (2013). Wnt Signaling Pathway in Rheumatoid Arthritis, with Special Emphasis on the Different Roles in Synovial Inflammation and Bone Remodeling. Cell Signal.25 (10), 2069–2078. 10.1016/j.cellsig.2013.04.002
76
Mohd JayaF. N.GarciaS. G.BorràsF. E.ChanG. C. F.FranquesaM. (2019). Paradoxical Role of Breg-Inducing Cytokines in Autoimmune Diseases. J. Translational Autoimmun.2, 100011. 10.1016/j.jtauto.2019.100011
77
NakamuraY.NawataM.WakitaniS. (2005). Expression Profiles and Functional Analyses of Wnt-Related Genes in Human Joint Disorders. Am. J. Pathol.167 (1), 97–105. 10.1016/S0002-9440(10)62957-4
78
NakanoS.MorimotoS.SuzukiS.TsushimaH.YamanakaK.SekigawaI.et al (2015a). Immunoregulatory Role of IL-35 in T Cells of Patients with Rheumatoid Arthritis. Rheumatology54 (8), 1498–1506. 10.1093/rheumatology/keu528
79
NakanoS.MorimotoS.SuzukiS.TsushimaH.YamanakaK.SekigawaI.et al (2015b). Immunoregulatory Role of IL-35 in T Cells of Patients with Rheumatoid Arthritis. Rheumatology54 (8), 1498–1506. 10.1093/rheumatology/keu528
80
NiedbalaW.WeiX.-q.CaiB.HueberA. J.LeungB. P.McinnesI. B.et al (2007). IL-35 Is a Novel Cytokine with Therapeutic Effects against Collagen-Induced Arthritis through the Expansion of Regulatory T Cells and Suppression of Th17 Cells. Eur. J. Immunol.37 (11), 3021–3029. 10.1002/eji.200737810
81
NingX.JianZ.WangW. (2015). Low Serum Levels of Interleukin 35 in Patients with Rheumatoid Arthritis. Tohoku J. Exp. Med.237 (2), 77–82. 10.1620/tjem.237.77
82
ParhamC.ChiricaM.TimansJ.VaisbergE.TravisM.CheungJ.et al (2002). A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R. J. Immunol.168 (11), 5699–5708. 10.4049/jimmunol.168.11.5699
83
ParkH.LiZ.YangX. O.ChangS. H.NurievaR.WangY.-H.et al (2005). A Distinct Lineage of CD4 T Cells Regulates Tissue Inflammation by Producing Interleukin 17. Nat. Immunol.6 (11), 1133–1141. 10.1038/ni1261
84
PengM.QiangL.XuY.LiC.LiT.WangJ. (2019). IL ‐35 Ameliorates Collagen‐induced Arthritis by Promoting TNF ‐α‐induced Apoptosis of Synovial Fibroblasts and Stimulating M2 Macrophages Polarization. FEBS J.286 (10), 1972–1985. 10.1111/febs.14801
85
PflanzS.TimansJ. C.CheungJ.RosalesR.KanzlerH.GilbertJ.et al (2002). IL-27, a Heterodimeric Cytokine Composed of EBI3 and P28 Protein, Induces Proliferation of Naive CD4+ T Cells. Immunity16 (6), 779–790. 10.1016/s1074-7613(02)00324-2
86
RamírezJ.CañeteJ. D. (2018). Anakinra for the Treatment of Rheumatoid Arthritis: a Safety Evaluation. Expert Opin. Drug Saf.17 (7), 727–732. 10.1080/14740338.2018.1486819
87
RehaumeL. M.MatigianN.MehdiA. M.LachnerN.BowermanK. L.DalyJ.et al (2019). IL-23 Favours Outgrowth of Spondyloarthritis-Associated Pathobionts and Suppresses Host Support for Homeostatic Microbiota. Ann. Rheum. Dis.78 (4), 494–503. 10.1136/annrheumdis-2018-214381
88
RemmersE. F.CosanF.KirinoY.OmbrelloM. J.AbaciN.SatoriusC.et al (2010). Genome-wide Association Study Identifies Variants in the MHC Class I, IL10, and IL23R-IL12RB2 Regions Associated with Behçet's Disease. Nat. Genet.42 (8), 698–702. 10.1038/ng.625
89
SaberT.VealeD. J.BaloghE.MccormickJ.NicanultaighS.ConnollyM.et al (2011). Toll-like Receptor 2 Induced Angiogenesis and Invasion Is Mediated through the Tie2 Signalling Pathway in Rheumatoid Arthritis. PLoS One6 (8), e23540. 10.1371/journal.pone.0023540
90
SafariF.FarajniaS.AryaM.ZarredarH.NasrolahiA. (2018). CRISPR and Personalized Treg Therapy: New Insights into the Treatment of Rheumatoid Arthritis. Immunopharmacology and Immunotoxicology40 (3), 201–211. 10.1080/08923973.2018.1437625
91
ScottB. B.ZaratinP. F.ColomboA.HansburyM. J.WinklerJ. D.JacksonJ. R. (2002). Constitutive Expression of Angiopoietin-1 and -2 and Modulation of Their Expression by Inflammatory Cytokines in Rheumatoid Arthritis Synovial Fibroblasts. J. Rheumatol.29 (2), 230–239.
92
ScottL. J. (2018). Correction to: Tocilizumab: A Review in Rheumatoid Arthritis. Drugs78 (2), 285. 10.1007/s40265-017-0856-4
93
ScottL. J. (2017). Sarilumab: First Global Approval. Drugs77 (6), 705–712. 10.1007/s40265-017-0724-2
94
SenM.ReifertJ.LauterbachK.WolfV.RubinJ. S.CorrM.et al (2002). Regulation of Fibronectin and Metalloproteinase Expression by Wnt Signaling in Rheumatoid Arthritis Synoviocytes. Arthritis Rheum.46 (11), 2867–2877. 10.1002/art.10593
95
ShenP.RochT.LampropoulouV.O’ConnorR. A.StervboU.HilgenbergE.et al (2014). IL-35-producing B Cells Are Critical Regulators of Immunity during Autoimmune and Infectious Diseases. Nature507 (7492), 366–370. 10.1038/nature12979
96
ShuiX. L.LinW.MaoC. W.FengY. Z.KongJ. Z.ChenS. M. (2017). Blockade of IL-17 Alleviated Inflammation in Rat Arthritis and MMP-13 Expression. Eur. Rev. Med. Pharmacol. Sci.21 (10), 2329–2337.
97
SongM.MaX. (2016). The Immunobiology of Interleukin-35 and its Regulation and Gene Expression. Adv. Exp. Med. Biol.941, 213–225. 10.1007/978-94-024-0921-5_10
98
StadtmauerE. A.FraiettaJ. A.DavisM. M.CohenA. D.WeberK. L.LancasterE.et al (2020). CRISPR-engineered T Cells in Patients with Refractory Cancer. Science367 (6481), eaba7365. 10.1126/science.aba7365
99
SuL.-C.LiuX.-Y.HuangA.-F.XuW.-D. (2018). Emerging Role of IL-35 in Inflammatory Autoimmune Diseases. Autoimmun. Rev.17 (7), 665–673. 10.1016/j.autrev.2018.01.017
100
SunW. K.BaiY.YiM. M.WuL. J.ChenJ. L.WuD. M.et al (2019). Expression of T Follicular Helper Lymphocytes with Different Subsets and Analysis of Serum IL-6, IL-17, TGF-β and MMP-3 Contents in Patients with Rheumatoid Arthritis. Eur. Rev. Med. Pharmacol. Sci.23 (1), 61–69. 10.26355/eurrev_201901_16748
101
SunY.LiuJ.WanL.WangF.QiY. (2015). [Xinfeng Capsule Increases Peripheral Blood BTLA Expression of CD19(+) and CD24(+) B Cells and Relieves Oxidative Stress Damage to Improve Cardiac Function of Patients with Rheumatoid Arthritis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi31 (1), 93–96.
102
SzekaneczZ.BesenyeiT.SzentpéteryÁ.KochA. E. (2010). Angiogenesis and Vasculogenesis in Rheumatoid Arthritis. Curr. Opin. Rheumatol.22 (3), 299–306. 10.1097/BOR.0b013e328337c95a
103
TaitW. E.HunterC. A.StumhoferJ. S. (2019). The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity50 (4), 851–870. 10.1016/j.immuni.2019.03.011
104
TanakaS.TanakaY.IshiguroN.YamanakaH.TakeuchiT. (2018). RANKL: A Therapeutic Target for Bone Destruction in Rheumatoid Arthritis. Mod. Rheumatol.28 (1), 9–16. 10.1080/14397595.2017.1369491
105
TarditoS.MartinelliG.SoldanoS.PaolinoS.PaciniG.PataneM.et al (2019). Macrophage M1/M2 Polarization and Rheumatoid Arthritis: A Systematic Review. Autoimmun. Rev.18 (11), 102397. 10.1016/j.autrev.2019.102397
106
TeymouriM.PirroM.FallarinoF.GargaroM.SahebkarA. (2018). IL-35, a Hallmark of Immune-Regulation in Cancer Progression, Chronic Infections and Inflammatory Diseases. Int. J. Cancer143 (9), 2105–2115. 10.1002/ijc.31382
107
ThierfelderW. E.van DeursenJ. M.YamamotoK.TrippR. A.SarawarS. R.CarsonR. T.et al (1996). Requirement for Stat4 in Interleukin-12-Mediated Responses of Natural Killer and T Cells. Nature382 (6587), 171–174. 10.1038/382171a0
108
ThiolatA.DenysA.PetitM.BitonJ.LemeiterD.HerveR.et al (2014). Interleukin-35 Gene Therapy Exacerbates Experimental Rheumatoid Arthritis in Mice. Cytokine69 (1), 87–93. 10.1016/j.cyto.2014.05.015
109
TurkS. A.van Beers-TasM. H.van SchaardenburgD. (2014). Prediction of Future Rheumatoid Arthritis. Rheum. Dis. Clin. North America40 (4), 753–770. 10.1016/j.rdc.2014.07.007
110
VanderborghtB.LefereS.VlierbergheH. V.DevisscherL. (2020). The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells9 (11), 2382. 10.3390/cells9112382
111
VealeD. J.OrrC.FearonU. (2017). Cellular and Molecular Perspectives in Rheumatoid Arthritis. Semin. Immunopathol.39 (4), 343–354. 10.1007/s00281-017-0633-1
112
VeldhoenM.HockingR. J.AtkinsC. J.LocksleyR. M.StockingerB. (2006). TGFβ in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T Cells. Immunity24 (2), 179–189. 10.1016/j.immuni.2006.01.001
113
WangD.LeiL. (2021). Interleukin‐35 Regulates the Balance of Th17 and Treg Responses during the Pathogenesis of Connective Tissue Diseases. Int. J. Rheum. Dis.24 (1), 21–27. 10.1111/1756-185X.13962
114
WangR. X.YuC. R.DambuzaI. M.MahdiR. M.DolinskaM. B.SergeevY. V.et al (2014). Interleukin-35 Induces Regulatory B Cells that Suppress Autoimmune Disease. Nat. Med.20 (6), 633–641. 10.1038/nm.3554
115
WangS. Y.LiuY. Y.YeH.GuoJ. P.LiR.LiuX.et al (2011). Circulating Dickkopf-1 Is Correlated with Bone Erosion and Inflammation in Rheumatoid Arthritis. J. Rheumatol.38 (5), 821–827. 10.3899/jrheum.100089
116
WangW.ShaoS.JiaoZ.GuoM.XuH.WangS. (2012). The Th17/Treg Imbalance and Cytokine Environment in Peripheral Blood of Patients with Rheumatoid Arthritis. Rheumatol. Int.32 (4), 887–893. 10.1007/s00296-010-1710-0
117
WangX.ZhongW. (2015). Isorhamnetin Attenuates Collagen-Induced Arthritis via Modulating Cytokines and Oxidative Stress in Mice. Int. J. Clin. Exp. Med.8 (9), 16536–16542.
118
WangZ.LiuJ. Q.LiuZ.ShenR.ZhangG.XuJ.et al (2013). Tumor-derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis. J. Immunol.190 (5), 2415–2423. 10.4049/jimmunol.1202535
119
WilliamsC. L.SchillingM. M.ChoS. H.LeeK.WeiM.Aditi, BoothbyM.et al (2013). STAT4 and T-Bet Are Required for the Plasticity of IFN-γ Expression across Th2 Ontogeny and Influence Changes in Ifng Promoter DNA Methylation. J. Immunol.191 (2), 678–687. 10.4049/jimmunol.1203360
120
WojdasiewiczP.WajdaA.HaladyjE.Romanowska-ProchnickaK.Felis-GiemzaA.Nalecz-JanikJ.et al (2019). IL-35, TNF-Alpha, BAFF, and VEGF Serum Levels in Patients with Different Rheumatic Diseases. Reumatologia57 (3), 145–150. 10.5114/reum.2019.86424
121
WuS.LiY.LiY.YaoL.LinT.JiangS.et al (2016a). Interleukin-35 Attenuates Collagen-Induced Arthritis through Suppression of Vascular Endothelial Growth Factor and its Receptors. Int. Immunopharmacol.34, 71–77. 10.1016/j.intimp.2016.02.018
122
WuS.LiY.LiY.YaoL.LinT.JiangS.et al (2016b). Interleukin-35 Attenuates Collagen-Induced Arthritis through Suppression of Vascular Endothelial Growth Factor and its Receptors. Int. Immunopharmacol.34, 71–77. 10.1016/j.intimp.2016.02.018
123
WuS.LiY.LiY.YaoL.LinT.JiangS.et al (2016c). Interleukin-35 Attenuates Collagen-Induced Arthritis through Suppression of Vascular Endothelial Growth Factor and its Receptors. Int. Immunopharmacol.34, 71–77. 10.1016/j.intimp.2016.02.018
124
WuS.LiY.YaoL.LiY.JiangS.GuW.et al (2018). Interleukin-35 Inhibits Angiogenesis through STAT1 Signalling in Rheumatoid Synoviocytes. Clin. Exp. Rheumatol.36 (2), 223–227.
125
WuX.HeB.LiuJ.FengH.MaY.LiD.et al (2016). Molecular Insight into Gut Microbiota and Rheumatoid Arthritis. Int. J. Mol. Sci.17 (3), 431. 10.3390/ijms17030431
126
XieF.HuQ.CaiQ.YaoR.OuyangS. (2020). IL-35 Inhibited Th17 Response in Children with Allergic Rhinitis. ORL J. Otorhinolaryngol. Relat. Spec.82 (1), 47–52. 10.1159/000504197
127
XieQ.XuW. D.PanM.LanY. Y.LiuX. Y.SuL. C.et al (2021). Association of IL-35 Expression and Gene Polymorphisms in Rheumatoid Arthritis. Int. Immunopharmacol.90, 107231. 10.1016/j.intimp.2020.107231
128
YagoT.NankeY.KawamotoM.KobashigawaT.YamanakaH.KotakeS. (2018). IL-35 Inhibits Human Osteoclastogenesis from Monocytes Induced by Receptor-Activator of NF-kappaB Ligand. Cent. Eur. J. Immunol.43 (2), 148–154. 10.5114/ceji.2018.77384
129
YangJ.YangM.HtutT. M.OuyangX.HaniduA.LiX.et al (2008). Epstein-Barr Virus-Induced Gene 3 Negatively Regulates IL-17, IL-22 and RORgamma T. Eur. J. Immunol.38 (5), 1204–1214. 10.1002/eji.200838145
130
YinL.GeY.YangH.PengQ.LuX.ZhangY.et al (2016). The Clinical Utility of Serum IL-35 in Patients with Polymyositis and Dermatomyositis. Clin. Rheumatol.35 (11), 2715–2721. 10.1007/s10067-016-3347-1
131
ZhangX.ZhangX.ZhuangL.XuC.LiT.ZhangG.et al (2018). Decreased Regulatory T-Cell Frequency and Interleukin-35 Levels in Patients with Rheumatoid Arthritis. Exp. Ther. Med.16 (6), 5366–5372. 10.3892/etm.2018.6885
132
ZhaoM.GuJ.WangZ. (2020). B Cells in Crohn's Patients Presented Reduced IL-35 Expression Capacity. Mol. Immunol.118, 124–131. 10.1016/j.molimm.2019.12.005
133
ZhuJ.WangY.LiD.ZhangH.GuoZ.YangX. (2020). Interleukin-35 Promotes Progression of Prostate Cancer and Inhibits Anti-tumour Immunity. Cancer Cel Int20, 487. 10.1186/s12935-020-01583-3
134
ZouJ. M.QinJ.LiY. C.WangY.LiD.ShuY.et al (2017). IL-35 Induces N2 Phenotype of Neutrophils to Promote Tumor Growth. Oncotarget8 (20), 33501–33514. 10.18632/oncotarget.16819
Summary
Keywords
rheumatoid arthritis, IL-35, IL-12 family, treg, Th17, article highlights
Citation
Xin PL, Jie LF, Cheng Q, Bin DY and Dan CW (2021) Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis. Front. Pharmacol. 12:655114. doi: 10.3389/fphar.2021.655114
Received
18 January 2021
Accepted
13 April 2021
Published
13 May 2021
Volume
12 - 2021
Edited by
Emanuela Ricciotti, University of Pennsylvania, United States
Updates
Copyright
© 2021 Xin, Jie, Cheng, Bin and Dan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cheng Wen Dan, sunyccc@126.com; Du Yi Bin, dodo1108@163.com
† These authors have contributed equally to this work
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.